Atorvastatin and simvastatin exhibit stronger proliferation inhibition and apoptosis induction in triple-negative breast cancer (TNBC) cells, particularly those harboring p53 mutations. Their combination with IGF-1R inhibitors or chemotherapeutic agents such as doxorubicin further enhances therapeutic efficacy. Here, TP53 is linked to triple-negative breast carcinoma.